Reports Q1 revenue $37,255 vs. $129,799 last year. "This was a productive quarter for Sonnet and one of which we are particularly proud. We believe the successful early clinical data we announced sets the stage for SON-1010 as a potentially best-in-class IL-12 therapeutic candidate with unique properties for targeting the tumor microenvironment," commented Pankaj Mohan, Ph.D., Founder and CEO. "Our prioritized business development initiatives culminated in the work Janssen is currently undertaking to evaluate three of our pipeline assets. We continue to progress our platform with our first bispecific, bifunctional pipeline compound, SON-1210, a first-in-class combination of interleukins 12 and 15 and we look forward to delivering on our 2023 research and development initiatives while remaining focused on partnering as a key component of our strategy."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SONN:
- Sonnet BioTherapeutics $15M Secondary priced at $1.08
- Sonnet announces pricing of $15M underwritten public offering
- Sonnet completes two IND-enabling toxicology studies with SON-1210
- Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
- Sonnet BioTherapeutics announces data in Phase 1 trial of SON-1010
